Presentation Impact of Bivalirudin and Paclitaxel-Eluting Stents on Outcomes in Patients Undergoing Primary PCI of the LAD Presenter: Jochen W?hrle July 09, 2013
Presentation Heparin vs. Bivalirudin in Patients with NSTE-ACS Undergoing PCI Presenter: Oskar Anger?s May 23, 2013
Presentation Hemorrhagic and Ischemic Outcomes After Bivalirudin vs. Heparin During CAS Presenter: Siddharth A. Wayangankar April 19, 2013
Presentation Preprocedural Estimate of Individualized Bleeding Risk Impacts Physicians’ Bivalirudin Use During PCI Presenter: S. C. Rao March 05, 2013
Presentation TCT 2013 Impact of bivalirudin on peri-procedural events in patients undergoing rotational atherectomy: a subanalysis of the randomized ROTAXUS trial Presenter: Mohamed Abdel-Wahab, Ahmed Khattab, Heinz Joachim B?ttner, Ralph Toelg, Volker Geist, Thomas Meinertz, Franz-Josef Neumann, Gert Richardt January 31, 2013
Presentation TCT 2013 Heparin Versus Bivalirudin– In-hospital And 30 Day MACE In Patients Having DES Implantation Presenter: Evan Shlofmitz, Richard Shlofmitz, Simcha Pollack, Elizabeth Cormier, Elizabeth Haag, Nathaniel Reichek January 31, 2013
Presentation TCT 2013 Ecarin Clotting Time (ECT) more accurately reflects bivalirudin concentration than Activated Clotting Time (ACT) in patients undergoing Percutaneous Coronary Intervention using... Presenter: Ronan Margey, Helen Ridgway, Richard Rullman, Jeff Spencer, Ronan Margey, Iris McNulty, Aditya Mangla, Sotir Polena, Daniel Soffer, Ik-Kyung Jang January 31, 2013
Presentation TCT 2013 Can the Rate of Acute Stent Thrombosis with Bivalirudin Anticoagulation During Primary PCI in STEMI be Reduced with Modified Pharmacologic Regimens? Presenter: Andreas Baumbach, Harold Dauerman, Bernardo Cortese, Martial Hamon, Jayne Prats, Efthymios Deliargyris, Roxana Mehran, Gregg Stone January 31, 2013
Presentation TCT 2012 Glycoprotein IIb/IIIa Inhibitors in the Era of Bivalirudin and New Oral Antiplatelet Agents: Is Intracoronary Application the Standard of Choice? Presenter: Rajesh Dave October 25, 2012
Presentation TCT 2012 Debate: Bivalirudin Is the Preferred Anticoagulant Strategy During STEMI! Presenter: Roxana Mehran October 25, 2012
Presentation TCT 2012 TCT-52. Bivalirudin Reduces Cardiac Mortality in Patients with and Without Major Bleeding: The HORIZONS-AMI Trial Presenter: Gregg Stone October 23, 2012
Presentation TCT 2012 TCT-50. Influence of Age on Clinical Outcomes in Patients with NSTEMI Undergoing Treatment with Abciximab plus Unfractionated Heparin vs. Bivalirudin: Analysis of the ISAR... Presenter: Lamin King October 23, 2012
Presentation TCT 2012 Radial Approach Offers No Benefit Over Femoral Plus Bivalirudin! Presenter: James Hermiller Jr October 23, 2012
Presentation Bivalirudin vs. Heparin Plus a GPI in Pts with NSTEMI Undergoing PCI After Clopidogrel Pretreatment Presenter: G. Ndrepepa October 18, 2012
Presentation Benefit of Bivalirudin Versus Heparin After Transradial and Transfemoral PCI Presenter: J. MacHaalany October 11, 2012
Presentation ACVS 2012 Bivalirudin Versus Heparin in STEMI Presenter: Colonel Anil Dhall August 03, 2012
Presentation Prognostic Value of High On-Clopidogrel Platelet Reactivity in Bivalirudin- vs. Abciximab-Treated NSTEMI Patients Presenter: Dirk Sibbing June 06, 2012
Presentation TCT Mediterranean 2012 Anticoagulation in ACS: Role of Bivalirudin Presenter: Gregg W. Stone May 04, 2012